1. Advances in Immunotherapy for Peanut Allergy

2. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

3. Introduction to Peanut Allergy Immunotherapy

4. OIT Phase 2 Study Design

5. OIT Phase 2 Study Results

6. OIT Phase 3 Study Efficacy

7. OIT Phase 3 Study Safety

8. EPIT Phase 3 Study Design

9. EPIT Phase 3 Study Results

10. Balancing Safety and Efficacy

11. Shared Decision-Making

12. Conclusions and Key Takeaways

13. Abbreviations